GO:0052651 monoacylglycerol catabolic process: Lysosomal Lipid Degradation Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0052651 (monoacylglycerol catabolic process) describes the biochemical breakdown of monoacylglycerol, a glycerol esterified with a single fatty acid.
• The term is a biological_process in the Gene Ontology and is closely linked to lysosomal lipid catabolism and bis(monoacylglycero)phosphate (BMP) metabolism.
• Key enzymes include PLA2G15, which acts as a BMP hydrolase and generates monoacylglycerol species in lysosomes.
• PLD3 and PLD4 synthesize S,S-BMP, a phospholipid required for efficient lipid degradation in lysosomes, indirectly supporting monoacylglycerol catabolic flux.
• LRRK2 kinase activity regulates Parkinson's disease-relevant lipids at the lysosome, connecting monoacylglycerol catabolism to neurodegeneration.
• Hepatic lipid remodeling during cold exposure directly regulates BMP lipids through phospholipase A2 group XV, linking monoacylglycerol catabolism to systemic metabolic adaptation.
Description
Monoacylglycerol catabolic process (GO:0052651) is defined in the Gene Ontology as the chemical reactions and pathways resulting in the breakdown of monoacylglycerol, any ester of glycerol in which any one of its hydroxyl groups has been acylated with a fatty acid, the other being non-esterified. This process is central to lysosomal lipid handling because monoacylglycerol is both a product and a substrate in the degradation of complex lipids such as bis(monoacylglycero)phosphate (BMP). Researchers studying lysosomal storage disorders, phospholipid remodeling, and neurodegenerative disease increasingly recognize that monoacylglycerol catabolic steps are not merely housekeeping reactions but are integrated into membrane quality control and lipid signaling. The discovery that PLA2G15 functions as a BMP hydrolase and that its targeting ameliorates lysosomal disease has placed monoacylglycerol-generating catabolic reactions at the center of therapeutic strategies for lysosomal dysfunction. Similarly, the identification of PLD3 and PLD4 as S,S-BMP synthases demonstrates that monoacylglycerol-containing phospholipids are essential for enabling lipid degradation in lysosomes. Because monoacylglycerol catabolic process intersects with BMP homeostasis, cholesterol trafficking, and cold-induced hepatic lipid remodeling, it represents a convergence point for metabolic, neurodegenerative, and lysosomal research. This article synthesizes authoritative QuickGO annotation data with verified PubMed literature to provide a research-grade overview of GO:0052651, its genes, mechanisms, disease relevance, and experimental models.
monoacylglycerol catabolic process At A Glance
| GO ID | GO:0052651 |
|---|---|
| GO term | monoacylglycerol catabolic process |
| Ontology | biological_process |
| Synonym | monoacylglycerol breakdown; monoacylglycerol catabolism; monoacylglycerol degradation |
| Major function | Breakdown of monoacylglycerol, a glycerol esterified with a single fatty acid, within cellular lipid catabolic pathways |
| Associated enzymes | PLA2G15 (BMP hydrolase), PLD3, PLD4, and other lysosomal phospholipases |
| Subcellular context | Lysosomal lipid degradation and membrane remodeling |
| Disease relevance | Lysosomal storage disorders, Parkinson's disease, metabolic lipid remodeling |
What Is GO:0052651?
In plain terms, GO:0052651 describes the set of biochemical reactions that break down monoacylglycerol, a molecule made of glycerol with one fatty acid attached. The QuickGO definition states that this process encompasses the chemical reactions and pathways resulting in the breakdown of monoacylglycerol, any ester of glycerol in which any one of its hydroxyl groups has been acylated with a fatty acid, the other being non-esterified. This process is a biological_process in the Gene Ontology and is synonymous with monoacylglycerol breakdown, monoacylglycerol catabolism, and monoacylglycerol degradation. It is mechanistically linked to lysosomal phospholipid catabolism, particularly the hydrolysis of bis(monoacylglycero)phosphate (BMP) by enzymes such as PLA2G15.
Why Is monoacylglycerol catabolic process Important in Cell Biology?
Monoacylglycerol catabolic process is important because it sits at the intersection of lysosomal lipid degradation, membrane phospholipid remodeling, and metabolic disease. The breakdown of monoacylglycerol is required for the turnover of bis(monoacylglycero)phosphate (BMP), a phospholipid that enables lipid degradation in lysosomes. When this process is impaired, lipids accumulate, lysosomal function declines, and disease-associated phenotypes emerge, as shown by studies linking PLA2G15-mediated BMP hydrolysis to lysosomal disease amelioration. Furthermore, LRRK2 kinase activity regulates Parkinson's disease-relevant lipids at the lysosome, implicating monoacylglycerol catabolic pathways in neurodegeneration. Hepatic lipid remodeling during cold exposure directly regulates BMP lipids through phospholipase A2 group XV, demonstrating that monoacylglycerol catabolism participates in systemic metabolic adaptation. Thus, understanding GO:0052651 is essential for researchers in lysosomal biology, neurodegeneration, and metabolic disease.
• Enables lysosomal degradation of BMP and other monoacylglycerol-containing phospholipids.
• Supports membrane lipid quality control and phospholipid remodeling.
• Links to lysosomal storage disorders through PLA2G15 and BMP hydrolase activity.
• Connects to Parkinson's disease via LRRK2-regulated lysosomal lipids.
• Participates in hepatic lipid remodeling during cold exposure.
• Influences intracellular cholesterol accumulation in NPC1 deficiency.
• Provides biomarkers for neurodegenerative diseases through lipid profiling.
• Represents a therapeutic target for ameliorating lysosomal disease.
• Integrates intra- and extralysosomal pathways for BMP synthesis and catabolism.
• Offers experimental tractability through CRISPR knockout and knock-in models of PLA2G15, PLD3, and PLD4.
What Happens During monoacylglycerol catabolic process?
Substrate recognition and lysosomal delivery
In simple terms: First, the cell delivers monoacylglycerol-containing lipids to the lysosome where they can be broken down.
Monoacylglycerol catabolic process begins with the delivery of monoacylglycerol-containing phospholipids, such as bis(monoacylglycero)phosphate (BMP), to the lysosomal compartment. BMP is synthesized by PLD3 and PLD4 as S,S-BMP, a key phospholipid enabling lipid degradation in lysosomes. Functionally overlapping intra- and extralysosomal pathways promote BMP synthesis in mammalian cells, ensuring that substrates for monoacylglycerol catabolism are available. This step is essential because lysosomal lipid degradation depends on BMP for proper enzyme function.
Enzymatic hydrolysis by PLA2G15 and related hydrolases
In simple terms: Enzymes in the lysosome cut the fatty acid off the monoacylglycerol-containing lipid.
The central catalytic step involves hydrolysis of BMP by PLA2G15, which functions as a BMP hydrolase and generates monoacylglycerol species. Targeting PLA2G15 ameliorates lysosomal disease, demonstrating that this hydrolytic step is rate-limiting in pathology. Hepatic lipid remodeling during cold exposure directly regulates BMP lipids by phospholipase A2 group XV, further confirming the role of this enzyme family in monoacylglycerol catabolic flux. The breakdown of monoacylglycerol is thus executed by lysosomal phospholipases that cleave acyl chains from glycerol backbones.
Monoacylglycerol breakdown and fatty acid release
In simple terms: After the fatty acid is removed, the remaining monoacylglycerol is further broken down into glycerol and free fatty acids.
Following initial hydrolysis, monoacylglycerol is further catabolized to release glycerol and free fatty acids. This step completes the breakdown of monoacylglycerol as defined by GO:0052651. The process is integrated with lysosomal lipid degradation pathways that require BMP for optimal activity. In NPC1 deficiency, phospholipid treatment reduces intracellular cholesterol accumulation, indicating that monoacylglycerol catabolic products influence cholesterol trafficking. The released fatty acids and glycerol can be reused or exported, linking this process to cellular energy metabolism.
Regulation by LRRK2 and disease-relevant signaling
In simple terms: Signaling proteins like LRRK2 can change how fast this breakdown happens, especially in brain cells.
LRRK2 kinase activity regulates Parkinson's disease-relevant lipids at the lysosome, including BMP and monoacylglycerol species. This regulation connects monoacylglycerol catabolic process to neurodegeneration and suggests that kinase inhibitors may modulate the pathway. Lipids are emerging biomarkers in neurodegenerative diseases, and monoacylglycerol-related lipids are part of this biomarker landscape. Thus, the catabolic process is not constitutive but subject to signaling control.
Integration with BMP homeostasis and therapeutic targeting
In simple terms: The breakdown of monoacylglycerol is part of a larger cycle that keeps lysosomal membranes healthy, and fixing it can treat disease.
Monoacylglycerol catabolic process is tightly coupled to BMP homeostasis, as BMP synthesis by PLD3/PLD4 and hydrolysis by PLA2G15 determine the pool of monoacylglycerol substrates. The Bis(monoacylglycero)-phosphate Hypothesis posits that BMP levels are critical for lysosomal function and that therapeutic avenues can target this pathway. Targeting PLA2G15 ameliorates lysosomal disease, providing proof of concept that modulating monoacylglycerol catabolism has therapeutic benefit. Therefore, GO:0052651 is both a metabolic node and a druggable pathway.
Key Genes Involved in GO:0052651 monoacylglycerol catabolic process
The following genes and proteins are experimentally implicated in monoacylglycerol catabolic process or its associated lysosomal lipid degradation pathways.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PLA2G15 | BMP hydrolase generating monoacylglycerol; phospholipase A2 group XV | Targeting ameliorates lysosomal disease; key enzyme in monoacylglycerol catabolism |
| PLD3 | Synthesizes S,S-BMP, a phospholipid enabling lipid degradation | Essential for lysosomal lipid degradation and BMP homeostasis |
| PLD4 | Synthesizes S,S-BMP in conjunction with PLD3 | Required for efficient lysosomal lipid catabolism |
| LRRK2 | Kinase regulating Parkinson's disease-relevant lipids at lysosome | Links monoacylglycerol catabolism to neurodegeneration |
| NPC1 | Cholesterol trafficking; phospholipid treatment reduces accumulation | Connects monoacylglycerol catabolic products to cholesterol handling |
| BMP-related genes | Intra- and extralysosomal BMP synthesis pathways | Functionally overlapping pathways promote BMP synthesis |
| Lipid biomarkers | Emerging biomarkers in neurodegenerative diseases | Monoacylglycerol-related lipids as disease markers |
| Lysosomal hydrolases | General lipid degradation enzymes | Support monoacylglycerol breakdown |
| Phospholipase A2 family | Hydrolyze acyl chains from phospholipids | Generate monoacylglycerol substrates |
| Glycerol kinases | Phosphorylate glycerol from monoacylglycerol breakdown | Downstream metabolism of catabolic products |
| Fatty acid transporters | Export or reuse released fatty acids | Link catabolism to energy metabolism |
| Lysosomal membrane proteins | Maintain lysosomal integrity for lipid degradation | Required for BMP-dependent catabolism |
| Autophagy-related genes | Deliver lipids to lysosomes | Support substrate availability for monoacylglycerol catabolism |
| Transcription factors for lipid metabolism | Regulate expression of lipid catabolic enzymes | Potential upstream control of GO:0052651 |
| Cold-response genes | Mediate hepatic lipid remodeling | Regulate BMP lipids via phospholipase A2 group XV |
| Neurodegeneration-associated genes | Modulate lysosomal lipid handling | Connect monoacylglycerol catabolism to Parkinson's disease |
How Is monoacylglycerol catabolic process Regulated?
Monoacylglycerol catabolic process is regulated at multiple levels. LRRK2 kinase activity regulates Parkinson's disease-relevant lipids at the lysosome, indicating that phosphorylation signaling controls the catabolic flux of monoacylglycerol-containing lipids. Hepatic lipid remodeling during cold exposure directly regulates bis(monoacylglycero)phosphate lipids by phospholipase A2 group XV, showing that environmental and metabolic cues modulate this pathway. The functionally overlapping intra- and extralysosomal pathways for BMP synthesis determine substrate availability for monoacylglycerol catabolism. Additionally, the Bis(monoacylglycero)-phosphate Hypothesis suggests that BMP levels are homeostatically controlled and that therapeutic targeting of BMP hydrolases can shift the balance. Thus, regulation occurs through kinase signaling, metabolic state, and substrate synthesis pathways.
monoacylglycerol catabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PLA2G15 | Lysosomal disease; BMP hydrolysis | CRISPR knockout in lysosomal disease cell models |
| PLD3 | Lysosomal lipid degradation; BMP synthesis | Knockout and knock-in of S,S-BMP synthesis |
| PLD4 | Lysosomal lipid degradation; BMP synthesis | Knockout and knock-in of S,S-BMP synthesis |
| LRRK2 | Parkinson's disease; lysosomal lipid regulation | Point mutation (G2019S) knock-in in neurons |
| NPC1 | Niemann-Pick type C; cholesterol accumulation | Knockout and phospholipid treatment models |
Lysosomal storage disorders
Monoacylglycerol catabolic process is directly linked to lysosomal storage disorders through the action of PLA2G15, a BMP hydrolase. Targeting PLA2G15 ameliorates lysosomal disease, demonstrating that impaired monoacylglycerol catabolism contributes to lysosomal dysfunction. PLD3 and PLD4 synthesize S,S-BMP, a key phospholipid enabling lipid degradation in lysosomes, and defects in this synthesis pathway would be expected to impair monoacylglycerol catabolism. The Bis(monoacylglycero)-phosphate Hypothesis provides a framework for understanding how BMP metabolism, including monoacylglycerol breakdown, is central to lysosomal function and therapeutic avenues.
Parkinson's disease and neurodegeneration
LRRK2 kinase activity regulates Parkinson's disease-relevant lipids at the lysosome, connecting monoacylglycerol catabolic process to neurodegeneration. Lipids are emerging biomarkers in neurodegenerative diseases, and monoacylglycerol-related lipid species may serve as indicators of lysosomal dysfunction in Parkinson's disease and related disorders. Because LRRK2 is a major genetic risk factor for Parkinson's disease, the regulation of lysosomal lipids by LRRK2 kinase activity suggests that modulating monoacylglycerol catabolism could be therapeutically relevant.
Metabolic and hepatic lipid remodeling
Hepatic lipid remodeling in cold exposure uncovers direct regulation of bis(monoacylglycero)phosphate lipids by phospholipase A2 group XV, linking monoacylglycerol catabolic process to systemic metabolic adaptation. In NPC1 deficiency, molecular determinants of phospholipid treatment reduce intracellular cholesterol accumulation, indicating that monoacylglycerol catabolic products influence cholesterol trafficking. These findings suggest that GO:0052651 is relevant to metabolic disorders characterized by abnormal lipid storage and trafficking.
From monoacylglycerol catabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of PLA2G15 impair monoacylglycerol catabolism? | PLA2G15 knockout cell line |
| Does S,S-BMP synthesis require PLD3 and PLD4? | PLD3/PLD4 double knockout |
| How does LRRK2 kinase activity affect lysosomal lipids? | LRRK2 G2019S point mutation knock-in |
| Can phospholipid treatment rescue NPC1 cholesterol accumulation? | NPC1 knockout with phospholipid treatment |
| What are the intra- and extralysosomal BMP synthesis pathways? | Tagged knock-in of BMP synthesis enzymes |
| Does cold exposure regulate BMP lipids via PLA2G15? | Overexpression of phospholipase A2 group XV in hepatocytes |
How to Study the monoacylglycerol catabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Lipidomics / mass spectrometry | Monoacylglycerol and BMP species | Quantify catabolic flux in cells and tissues |
| CRISPR knockout | Loss-of-function effects on lipid catabolism | Validate PLA2G15, PLD3, PLD4 roles |
| CRISPR knock-in | Mutant protein function in lysosomal lipid regulation | Study LRRK2 G2019S in Parkinson's models |
| Fluorescence imaging | Lysosomal lipid accumulation and morphology | Assess NPC1 cholesterol trafficking |
| Enzymatic activity assay | BMP hydrolase activity | Measure PLA2G15 catalysis |
| RNA-seq | Expression of lipid catabolic genes | Identify regulators of GO:0052651 |
| Proteomics | Protein interactions in lysosomal lipid degradation | Map BMP synthesis and catabolism complexes |
| Biomarker profiling | Lipid biomarkers in neurodegenerative disease | Correlate monoacylglycerol lipids with disease |
Lipidomics and mass spectrometry
Lipidomics using mass spectrometry is essential for measuring monoacylglycerol and BMP species in cells and tissues. Studies of hepatic lipid remodeling during cold exposure used lipidomic profiling to uncover direct regulation of BMP lipids by phospholipase A2 group XV. Lipid biomarkers are emerging in neurodegenerative diseases, and mass spectrometry-based lipidomics can quantify monoacylglycerol-related lipids in patient samples. This method provides direct evidence of monoacylglycerol catabolic process activity.
CRISPR knockout and knock-in models
CRISPR knockout of PLA2G15, PLD3, and PLD4 enables functional dissection of monoacylglycerol catabolic process. Targeting PLA2G15 ameliorates lysosomal disease, and knockout models can confirm its role as a BMP hydrolase. PLD3 and PLD4 knockout models demonstrate the requirement for S,S-BMP synthesis in lysosomal lipid degradation. Knock-in of LRRK2 mutations allows study of Parkinson's disease-relevant lipid regulation.
Fluorescence imaging and lysosomal probes
Imaging lysosomal morphology and lipid accumulation using fluorescent probes can assess the functional consequences of monoacylglycerol catabolic process disruption. Studies of NPC1 deficiency used phospholipid treatment to reduce intracellular cholesterol accumulation, which can be monitored by imaging. Lysosomal lipid degradation enabled by BMP can be visualized with lipid-specific dyes. These methods complement biochemical assays.
Enzymatic activity assays
In vitro enzymatic assays using recombinant PLA2G15 or phospholipase A2 group XV can measure BMP hydrolase activity and monoacylglycerol generation. These assays are critical for confirming that candidate genes directly catalyze steps in monoacylglycerol catabolic process. Coupled with lipidomics, they provide mechanistic insight into substrate specificity and kinetics.
How CRISPR Can Be Used to Study GO:0052651 monoacylglycerol catabolic process
Knockout
CRISPR knockout of PLA2G15, PLD3, or PLD4 is used to determine whether these genes are required for monoacylglycerol catabolic process. Targeting PLA2G15 ameliorates lysosomal disease, and knockout models can confirm loss of BMP hydrolase activity. PLD3 and PLD4 knockout models demonstrate the requirement for S,S-BMP synthesis in lysosomal lipid degradation. These models are essential for causal inference in GO:0052651 research.
Point Mutation
Point mutation knock-in of LRRK2 (e.g., G2019S) allows study of how kinase activity regulates Parkinson's disease-relevant lipids at the lysosome, including monoacylglycerol species. Such models are critical for understanding how disease-associated mutations alter monoacylglycerol catabolic process. Point mutations in PLA2G15 catalytic residues can also be introduced to dissect enzymatic mechanism.
Knock-in
Tagged knock-in of BMP synthesis enzymes enables visualization and purification of protein complexes involved in monoacylglycerol catabolic process. Knock-in of S,S-BMP synthesis genes can rescue loss-of-function phenotypes in PLD3/PLD4 knockout cells. These models help define the intra- and extralysosomal pathways that promote BMP synthesis.
Overexpression
Overexpression of phospholipase A2 group XV or PLA2G15 can enhance monoacylglycerol catabolic flux and reduce BMP levels, as shown in hepatic lipid remodeling studies. Overexpression models are useful for testing whether increased catabolic activity protects against lipid accumulation. They also allow biochemical purification of enzymes for activity assays.
How EDITGENE Supports monoacylglycerol catabolic process Research
Researchers studying monoacylglycerol catabolic process-related genes often need to determine whether a candidate gene is causally involved in lysosomal lipid degradation, BMP homeostasis, or disease-associated lipid accumulation. EDITGENE provides CRISPR-based cell model services to enable these causal experiments.
Contact EDITGENE today to design your custom CRISPR model for monoacylglycerol catabolic process research.
Frequently Asked Questions About monoacylglycerol catabolic process
What is monoacylglycerol catabolic process?
Monoacylglycerol catabolic process (GO:0052651) is the set of biochemical reactions that break down monoacylglycerol, a glycerol esterified with a single fatty acid, as defined by the Gene Ontology.
What genes are involved in monoacylglycerol catabolic process?
Key genes include PLA2G15, which acts as a BMP hydrolase, and PLD3 and PLD4, which synthesize S,S-BMP, a phospholipid enabling lipid degradation in lysosomes.
What is the GO ID for monoacylglycerol catabolic process?
The GO ID is GO:0052651, a biological_process term in the Gene Ontology.
How is monoacylglycerol catabolic process linked to lysosomal disease?
Targeting PLA2G15, a BMP hydrolase, ameliorates lysosomal disease, indicating that impaired monoacylglycerol catabolism contributes to lysosomal dysfunction.
What is the role of PLA2G15 in monoacylglycerol catabolism?
PLA2G15 is a BMP hydrolase that generates monoacylglycerol species in lysosomes and is a key enzyme in monoacylglycerol catabolic process.
How does LRRK2 affect monoacylglycerol catabolic process?
LRRK2 kinase activity regulates Parkinson's disease-relevant lipids at the lysosome, including monoacylglycerol-containing lipids, linking the pathway to neurodegeneration.
What methods are used to study monoacylglycerol catabolic process?
Lipidomics, CRISPR knockout, enzymatic activity assays, fluorescence imaging, and RNA-seq are commonly used to study this process.
Is monoacylglycerol catabolic process involved in Parkinson's disease?
Yes, LRRK2 kinase activity regulates Parkinson's disease-relevant lipids at the lysosome, connecting monoacylglycerol catabolism to neurodegeneration.
What is bis(monoacylglycero)phosphate and how is it related?
Bis(monoacylglycero)phosphate (BMP) is a phospholipid synthesized by PLD3 and PLD4 that enables lipid degradation in lysosomes and is hydrolyzed by PLA2G15 to generate monoacylglycerol.
How can CRISPR help study monoacylglycerol catabolic process?
CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of genes such as PLA2G15, PLD3, PLD4, and LRRK2 in monoacylglycerol catabolic process.
Conclusion
Monoacylglycerol catabolic process (GO:0052651) is a biologically_process term that describes the breakdown of monoacylglycerol, a reaction central to lysosomal lipid degradation and BMP homeostasis. Research has identified PLA2G15 as a BMP hydrolase whose targeting ameliorates lysosomal disease, and PLD3/PLD4 as S,S-BMP synthases required for lipid degradation. The pathway is regulated by LRRK2 kinase activity and hepatic lipid remodeling, linking it to Parkinson's disease and metabolic adaptation. CRISPR-based cell models are powerful tools for dissecting the causal roles of these genes, and EDITGENE provides comprehensive services to support such research.
References
- 1. Medoh UN et al.. 2024. The Bis(monoacylglycero)-phosphate Hypothesis: From Lysosomal Function to Therapeutic Avenues.. Annu Rev Biochem 93(1):447-469 PMID: 38603559
- 2. Nyame K et al.. 2025. PLA2G15 is a BMP hydrolase and its targeting ameliorates lysosomal disease.. Nature 642(8067):474-483 PMID: 40335701
- 3. Singh S et al.. 2024. PLD3 and PLD4 synthesize S,S-BMP, a key phospholipid enabling lipid degradation in lysosomes.. Cell 187(24):6820-6834.e24 PMID: 39423811
- 4. Maloney MT et al.. 2025. LRRK2 kinase activity regulates Parkinson's disease-relevant lipids at the lysosome.. Mol Neurodegener 20(1):89 PMID: 40770658
- 5. Bulfon D et al.. 2024. Functionally overlapping intra- and extralysosomal pathways promote bis(monoacylglycero)phosphate synthesis in mammalian cells.. Nat Commun 15(1):9937 PMID: 39548099
- 6. Wei J et al.. 2023. Lipids as Emerging Biomarkers in Neurodegenerative Diseases.. Int J Mol Sci 25(1) PMID: 38203300
- 7. Davidson JW et al.. 2025. Hepatic lipid remodeling in cold exposure uncovers direct regulation of bis(monoacylglycero)phosphate lipids by phospholipase A2 group XV.. Cell Metab 37(6):1413-1425.e6 PMID: 40373767
- 8. Deng S et al.. 2024. Molecular determinants of phospholipid treatment to reduce intracellular cholesterol accumulation in NPC1 deficiency.. J Biol Chem 300(11):107889 PMID: 39395801
